NCT04944966View on ClinicalTrials.gov

Safety and Efficacy of Maytenus Senegalensis for the Treatment of Uncomplicated Malaria

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 2, 2021

Primary Completion Date

September 25, 2022

Study Completion Date

September 25, 2022

Conditions
Malaria
Interventions
DRUG

Maytenus Senegalensis

"* Maytenus senegalensis (Malherbal) has a very long history of safe medicinal use in Africa in adult as well as infants and children. It will be administered orally at a dose of 800mg 8 hourly for 4 days.~* Artemether 20mg/lumefantrine 120mg"

Trial Locations (1)

Unknown

Bagamoyo Clinical Trial Facility, Bagamoyo

All Listed Sponsors
collaborator

Swiss Tropical & Public Health Institute

OTHER

collaborator

Muhimbili University of Health and Allied Sciences

OTHER

collaborator

National Institute for Medical Research, Tanzania

OTHER_GOV

lead

Ifakara Health Institute

OTHER